Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas: A Randomized Clinical Trial.

IMPORTANCE Cutaneous leiomyomas can be associated with severe paroxysmal pain in which nerve conduction may have a key role. Medical management of painful cutaneous leiomyomas is generally unsatisfactory. OBJECTIVE To assess the efficacy of intralesional botulinum toxin A in the management of pain associated with cutaneous leiomyomas. DESIGN, SETTING, AND PARTICIPANTS Randomized, double-blind, placebo-controlled pilot study conducted from January 5, 2009, to March 27, 2014. The setting was a single-center study at the National Institutes of Health among participants 18 years or older with cutaneous leiomyomas characterized by pain at least once weekly and pain of at least 4 on a pain scale ranging from 0 to 10. INTERVENTIONS Eighteen participants were randomized to receive intralesional botulinum toxin A (5 U per 1 cm2) or equivalent volumes of intralesional saline placebo. MAIN OUTCOMES AND MEASURES The primary outcomes were the differences in average lesional pain assessed by the Brief Pain Inventory and visual analog scale before and after ice provocation over a 4-week period. RESULTS No significant difference in average lesional pain was observed between the study arms. Decreased pain was reported in the botulinum toxin vs placebo arms by visual analog scale scores before ice provocation (median, 0.00; range, -3.30 to 0.70 for botulinum toxin and median, 0.40; range, -1.30 to 1.50 for placebo; P = .06); however, this finding was nonsignificant. No significant difference was observed in change in pain after ice provocation. A significant difference was seen between the arms in skin-related quality of life by total Dermatology Life Quality Index (median, -4.00; range, -8.00 to 2.00 for botulinum toxin and median, 0.00; range, -1.00 to 4.00 for placebo; P = .007) and with the specific skin pain-related question on the Dermatology Life Quality Index (median, -1.00; range, -2.00 to 1.00 for botulinum toxin and median, 0.00; range, -1.00 to 0.00 for placebo; P = .048). No significant difference was found in pain as ascertained by Patient Global Impression of Change at week 4. No serious adverse events related to botulinum toxin use were observed. CONCLUSIONS AND RELEVANCE The use of botulinum toxin to treat painful cutaneous leiomyomas was associated with improved quality of life and with a trend toward improved pain at rest. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00971620.

[1]  F. Y. Asiri,et al.  Efficacy of honey in comparison to topical corticosteroid for treatment of recurrent minor aphthous ulceration: a randomized, blind, controlled, parallel, double-center clinical trial. , 2014, Quintessence international.

[2]  Alexander E T Finlayson,et al.  Hippocrates on ulcers. , 2013, JAMA dermatology.

[3]  A. Jull,et al.  Honey as a topical treatment for wounds. , 2013, The Cochrane database of systematic reviews.

[4]  A. Blitzer,et al.  Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. , 2012, Journal of drugs in dermatology : JDD.

[5]  G. Hruza,et al.  Granuloma faciale treated with 595-nm pulsed dye laser. , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[6]  F. Brandt.  Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  A. Nasir,et al.  Topical botulinum toxin. , 2010, The Journal of clinical and aesthetic dermatology.

[8]  P. Čapek,et al.  Sensing the Deadliest Toxin: Technologies for Botulinum Neurotoxin Detection , 2010, Toxins.

[9]  E. Adışen,et al.  A new indication of botulinum toxin: leiomyoma-related pain. , 2009, Journal of the American Academy of Dermatology.

[10]  A. Tosca,et al.  Botulinum Toxin Type A – Treatment of a Patient with Multiple Cutaneous Piloleiomyomas , 2008, Dermatology.

[11]  J. Farrar,et al.  Core outcome measures for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[12]  C. Lyon,et al.  Successful treatment of pain in two patients with cutaneous leiomyomata with the oral alpha‐1 adrenoceptor antagonist, doxazosin , 2004, The British journal of dermatology.

[13]  J. Farrar,et al.  Core outcome domains for chronic pain clinical trials: IMMPACT recommendations , 2003, Pain.

[14]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[15]  C. Argoff.  A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain , 2002, The Clinical journal of pain.

[16]  J. Arezzo.  Possible Mechanisms for the Effects of Botulinum Toxin on Pain , 2002, The Clinical journal of pain.

[17]  L. Aaltonen,et al.  Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Tobin,et al.  Hair-cycle-associated remodeling of the peptidergic innervation of murine skin, and hair growth modulation by neuropeptides. , 2001, The Journal of investigative dermatology.

[19]  C. Fletcher,et al.  Cutaneous pilar leiomyoma: clinicopathologic analysis of 53 lesions in 45 patients. , 1997, The American Journal of dermatopathology.

[20]  L. Pearce,et al.  Histologic assessment of dose‐related diffusion and muscle fiber response after therapeutic botulinum a toxin injections , 1994, Movement disorders : official journal of the Movement Disorder Society.

[21]  S. Whittaker,et al.  Pharmacological modulation of cold‐induced pain in cutaneous leiomyomata , 1988, The British journal of dermatology.

[22]  M. Niemi,et al.  HISTOCHEMICAL STUDIES ON CUTANEOUS LEIOMYOMATOSIS. , 1963, The British journal of dermatology.